Pliant Therapeutics Inc expected to post a loss of 77 cents a share - Earnings Preview

Pliant Therapeutics

03/05/2024 12:53

* Pliant Therapeutics Inc  PLRX.OQ   PLRX.O  is expected
to show a
fall in quarterly revenue when it reports  results on May 7
(estimated) for the period ending March 31 2024
    * The South San Francisco California-based  company is
expected to
report a 65.1% decrease in revenue to $464.5 thousand from $1.33
million a year ago, according to the mean estimate from 10
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Pliant Therapeutics Inc
is for
a loss of 77 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 14 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 0.1%
in the last three months. ​
    * Wall Street's median 12-month price target for Pliant
Therapeutics Inc is $43.00​, above​ its last closing price
of $13.25. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -0.77       -0.81      -0.69     Beat    15.2
 Sep. 30 2023  -0.76       -0.77      -0.70     Beat    9.7
 Jan. 1 0001   -0.72       -0.71      -0.70     Beat    1.9​
 Mar. 31 2023  -0.65       -0.67      -0.67     Met     -0.2
 ​​Dec.        -0.70       -0.70      -0.72     Missed  -2.8
 31 2022                                                
 Sep. 30 2022  -0.74       -0.74      -0.65     Beat    12.3​
 Jun. 30 2022  -0.82       -0.81      -0.82     Missed  -1
 Mar. 31 2022  -0.73       -0.75      -0.78     Missed  -4
 This summary was machine generated May 3 at 11:53 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)